US FDA Approves Merck's New Combination HIV Treatment
MRK sits 54% above its 52-week low of $73.31.
Summary
The U.S. Food and Drug Administration (FDA) has approved Merck's once-daily, oral, combination regimen for HIV infections. This significant regulatory win strengthens Merck's product pipeline and provides a new treatment option in the competitive HIV market. The approval is a positive development for the company, especially as its blockbuster oncology drug Keytruda faces future patent expiration and pricing pressures. This news also helps to offset a setback earlier today regarding Merck and Eisai's experimental kidney cancer treatment failing to meet its main goals. Traders will be closely monitoring the market reception and sales forecasts for this new HIV therapy.
At the time of this announcement, MRK was trading at $112.55 on NYSE in the Life Sciences sector, with a market capitalization of approximately $278.3B. The 52-week trading range was $73.31 to $125.14. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.